NSCLC

Latest News

Medicaid Enrollees Appear To Be Missing Out on Targeted Treatment for NSCLC, Harvard Researchers Find
Medicaid Enrollees Appear To Be Missing Out on Targeted Treatment for NSCLC, Harvard Researchers Find

January 25th 2023

1 out 3 Medicaid patients who might have benefited from targeted therapy —mainly Tagrisso and Alecensa — for metastatic lung cancer did not receive it, according to estimates by a trio Harvard-affiliated researchers.

Keytruda Plus Platinum-based Chemotherapy Comes Out on Top in Network Meta-analysis
Keytruda Plus Platinum-based Chemotherapy Comes Out on Top in Network Meta-analysis

September 27th 2021

The Mainstreaming  of Targeted Lung Cancer Treatment
The Mainstreaming of Targeted Lung Cancer Treatment

September 14th 2021

Research Identifies Mutational Signatures of Nonsmall Cell Lung Cancer Tumors in Never Smokers
Research Identifies Mutational Signatures of Nonsmall Cell Lung Cancer Tumors in Never Smokers

September 9th 2021

Hypofractionated Radiotherapy Fails to Extend Survival in NSCLC Patients Ineligible for Concurrent Chemoradiotherapy
Hypofractionated Radiotherapy Fails to Extend Survival in NSCLC Patients Ineligible for Concurrent Chemoradiotherapy

September 1st 2021

Video Interviews
Latest CME Events & Activities

2024 USCAP Satellite Symposia

March 25-27, 2024

Register Now!

What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations

View More

Community Practice Connections™: Guidebook for Community Oncology NSCLC Treating Teams to Administer EGFR Exon 20-Targeted Regimens

View More

1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™

View More

Advances In™ KRAS Inhibition: Modern Considerations In Targeting KRAS-Mutated Lung, Colorectal, And Pancreatic Cancers

View More

How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC

View More

Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies

View More

Community Practice Connections™: 20th Annual Winter Lung Conference

View More

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation–Positive NSCLC: A Lung Cancer Tumor Board

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

25th Annual International Lung Cancer Congress®

July 25-27, 2024

Register Now!

24th Annual International Lung Cancer Congress®

View More

Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care

View More

Community Practice Connections: 7th Annual School of Nursing Oncology™

View More

6th Annual Precision Medicine Symposium: An Illustrated Tumor Board

October 18-19, 2024

Register Now!

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

19th Annual New York Lung Cancers Symposium®

November 16, 2024

Register Now!

Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC

View More

Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings

View More

More News

© 2024 MJH Life Sciences

All rights reserved.